Search - tctmd.com

Displaying 1 - 20 of 102

Sort: Relevancy | Date

News Daily News

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

Yael L. Maxwell

January 21, 2026

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Features

Year in Review: Women’s Heart Health in the Spotlight

Caitlin E. Cox

December 23, 2025

News Opinion CV Team Dispatch

October 2025 Dispatch for the CV Team

L.A. McKeown

October 25, 2025

News Daily News

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

Michael O'Riordan

October 10, 2025

News Daily News

Risk Factors Present in Nearly All Patients Who Develop CVD

Michael O'Riordan

October 02, 2025

News Daily News

Lower-Calorie Mediterranean Diet Plus Exercise Boosts Diabetes Prevention

Todd Neale

August 25, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

Caitlin E. Cox

July 21, 2025

News Daily News

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

Michael O'Riordan

July 18, 2025

News Daily News

PRAGUE-25: Ablation Improves Rhythm Control, but Don’t Discount Lifestyle Changes

Todd Neale

July 14, 2025

News Daily News

Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board

Michael O'Riordan

June 25, 2025

News Daily News

Amylin Analogue Boosts Weight Loss When Added to GLP-1

L.A. McKeown

June 24, 2025

News Daily News

Majority of US Adults Have High Long-term Risk of CVD: NHANES

Michael O'Riordan

June 13, 2025

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

Michael O'Riordan

May 14, 2025

News Conference News European Congress on Obesity 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Michael O'Riordan

May 13, 2025

News Conference News European Congress on Obesity 2025

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Michael O'Riordan

May 12, 2025

News Daily News

Access to GLP-1 Drugs Unequal for US Patients With Obesity

Caitlin E. Cox

May 01, 2025

News Conference News THT 2025

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

Todd Neale

February 12, 2025

News Daily News

Global Study Shows Sugary Drinks Boosting Diabetes and CVD at Alarming Rates

L.A. McKeown

January 10, 2025

Advertisement

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Year in Review: Women’s Heart Health in the Spotlight

October 2025 Dispatch for the CV Team

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

Risk Factors Present in Nearly All Patients Who Develop CVD

Lower-Calorie Mediterranean Diet Plus Exercise Boosts Diabetes Prevention

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

PRAGUE-25: Ablation Improves Rhythm Control, but Don’t Discount Lifestyle Changes

Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board

Amylin Analogue Boosts Weight Loss When Added to GLP-1

Majority of US Adults Have High Long-term Risk of CVD: NHANES

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Access to GLP-1 Drugs Unequal for US Patients With Obesity

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

Global Study Shows Sugary Drinks Boosting Diabetes and CVD at Alarming Rates

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content